NCT00377780View on ClinicalTrials.gov

Liposomal Doxorubicin, Trastuzumab, and Docetaxel in HER2 Positive Metastatic Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Breast CancerNeoplasm Metastasis
Interventions
DRUG

Non pegylated liposomal doxorubicin, trastuzumab, docetaxel

max. 6 courses

Trial Locations (7)

6800 TA

Ziekenhuis Rijnstate, Arnhem

9400 RA

Wilhelmina Ziekenhuis, Assen

5602 ZA

Catharina-Ziekenhuis, Eindhoven

3083 AN

Ikazia Ziekenhuis, Rotterdam

5500 MB

Maxima Medisch Centrum, Veldhoven

5900 BX

VieCuri MC, Venlo

7100 GG

Streekziekenhuis Koningin Beatrix, Winterswijk

Sponsors

Collaborators (2)

Cephalon
Sanofi
All Listed Sponsors
collaborator

Cephalon

INDUSTRY

collaborator

Sanofi

INDUSTRY

lead

Laurence J.C. van Warmerdam

OTHER

NCT00377780 - Liposomal Doxorubicin, Trastuzumab, and Docetaxel in HER2 Positive Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter